Cost-effectiveness of catheter ablation in patients with ventricular tachycardia

Circulation

Volumn 101, Issue 3, 2000, Pages 280-288

  Calkins, Hugh ^a,d   Bigger Jr , J Thomas ^b   Ackerman, Stacey J ^c   Duff, Steven B ^c   Wilber, David ^e   Kerr, Robert A ^c   Bar Din, Miriam ^c   Beusterien, Kathleen M ^c   Strauss, Michael J ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UK   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e NONE

Author keywords

Catheter ablation; Cost benefit analysis; Tachyarrhythmias; Tachycardia

Indexed keywords

AMIODARONE;

ARTICLE; CATHETER ABLATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FOLLOW UP; HEALTH CARE COST; HEART VENTRICLE TACHYCARDIA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034711721     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.3.280     Document Type: Article

References (31)

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335: 1933-1940.
2. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
3. Zipes DP, Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. Circulation. 1995;92:59-65.
4. Miller JM, Kienzle MG, Harken AH, Joscphson ME. Subendocardial resection for ventricular tachycardia: predictors of surgical success. Circulation. 1984;70:624-631.
5. Strickberger SA, Man KC, Daoud EG, Goyal R, Brinkman K, Hasse C, Bogun F, Knight BP, Weiss R, Bahu M, Morady F. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation. 1997;96:1525-1531.
6. Ruffy R, Imran MA, Santel DJ, Wharton M. Radiofrequency delivery through a cooled catheter tip allows the creation of larger endomyocardial lesions in the ovine heart. J Cardiovasc Electrophysiol. 1995;6: 1089-1096.
7. Cardiac Pathways Premarket Approval for the Chilli. Cooled Ablation System, application number P980003, FDA approval February 2, 1999.
8. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NAM, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19:1323-1334.
9. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
10. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation. 1998;97:2129-2135.
11. Hogenhuis W, Stevens SK, Wang P, Wong JB, Manolis AS, Estes M III, Pauker SG. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. Circulation. 1993;88(5 pt 2):437-446.
12. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, Daniels N, Weinstein MC. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996: 82-123.
13. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
14. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991;324:1362-1365.
15. Schulman KA, Rubenstein LE, Click HA, Eisenberg JM. Relationships between sponsors and investigators in pharmacoeconomic and clinical research Pharmacoeconomics. 1995;7:206-220.
16. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996: 214-235.
17. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:247-275.
18. Physicians' Desk Reference. 52nd ed. Montvale, NJ; Medical Economics Company, Inc; 1998.
19. Rothman SA, Hsia HH, Cossu SF, Chmielewski L, Buxton AE, Miller JM. Radiofrequency catheter ablation of postinfarction ventricular tachycardia. Circulation. 1997;96:3499-3508.
20. Shmueli A. The SF-36 profile and health-related quality of life: an interpretative analysis. Qual Life Res. 1998;7:187-195.
21. Torrance GW, Boyle MH, Horwood SP. Application of multi attribute utility theory to measure social preferences for health states. Operation Res. 1982;30:1043-1069.
22. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc; 1998.
23. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
24. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers, US City Average, Medical Care, 1998. Washington, DC: US Department of Labor; 1998.
25. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276: 1172-1177.
26. Herre JM, Suavé MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, Goldberg H, Scheinman MM. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 1989;13:442-449.
27. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667-674.
28. Myers M, Peter T, Weiss D, Nalos PC, Gang ES, Oseran DS, Mandel WJ. Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. Am Heart J. 1990;119:8-14.
29. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77-82.
30. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. 1993;72:280-287.
31. Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefeld C, Zipes DP. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J. 1993;125:109-120.